|
|
Volumn 6, Issue 6, 2010, Pages 307-308
|
|
Editorial: The red wolf remains a wily foe
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABATACEPT;
ALPHA INTERFERON;
ANTIMALARIAL AGENT;
AZATHIOPRINE;
B CELL ACTIVATING FACTOR;
BELIMUMAB;
CD22 ANTIGEN;
CD40 LIGAND;
CYCLOPHOSPHAMIDE;
IMMUNOSUPPRESSIVE AGENT;
INTERLEUKIN 21;
INTERLEUKIN 6;
MYCOPHENOLIC ACID;
PLACEBO;
RITUXIMAB;
MONOCLONAL ANTIBODY;
TNFSF13B PROTEIN, HUMAN;
AUTOLOGOUS STEM CELL TRANSPLANTATION;
B LYMPHOCYTE;
CLINICAL TRIAL;
DRUG APPROVAL;
DRUG RESEARCH;
DRUG TARGETING;
DRUG TREATMENT FAILURE;
EDITORIAL;
EFFECT SIZE;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
IMMUNOPATHOGENESIS;
LIFE EXPECTANCY;
MEDICAL RESEARCH;
METHODOLOGY;
OUTCOME ASSESSMENT;
PATIENT CARE;
PATIENT SELECTION;
PRIORITY JOURNAL;
SAMPLE SIZE;
SURVIVAL RATE;
SYSTEMIC LUPUS ERYTHEMATOSUS;
T LYMPHOCYTE;
TREATMENT DURATION;
TREATMENT OUTCOME;
UNSPECIFIED SIDE EFFECT;
DRUG ANTAGONISM;
IMMUNOLOGY;
ANTIBODIES, MONOCLONAL;
B-CELL ACTIVATING FACTOR;
CLINICAL TRIALS AS TOPIC;
HUMANS;
LUPUS ERYTHEMATOSUS, SYSTEMIC;
|
|
EID: 77953223446
PISSN: 17594790
EISSN: 17594804
Source Type: Journal
DOI: 10.1038/nrrheum.2010.83 Document Type: Editorial |
|
Times cited : (2)
|
|
References (0)
|
